title: Fluoxetine vs placebo for depressive symptoms after stroke: failed randomised controlled trial.
abstract: BACKGROUND
  Growth in antidepressant prescribing is a well-recognised phenomenon in developed countries. In stroke care, the evidence of effectiveness from systematic reviews is surprisingly weak. We therefore decided to undertake a randomised controlled trial comparing fluoxetine to placebo.
  
  
  METHODS
  Double blind placebo-controlled trial. Cases were high-scorers on the GHQ-28 and we applied minimal exclusion criteria.
  
  
  RESULTS
  Despite screening 614 patients we were able to randomise only one into the trial. High rates of refusal to participate and exclusions due to physical ill health were coupled with high rates of prescribing among stroke clinicians, to cause this recruitment problem.
  
  
  CONCLUSIONS
  In addition to the predicted practical problems of conducting an RCT in an elderly frail population, it became clear that most clinicians are not in equipoise about the value of antidepressant medication despite the lack of strong evidence for its effectiveness.
authors.affiliation: Faculty of Medicine and Health, University of Leeds.
authors.forename: M
authors.initials: M
authors.lastname: Ruddell
authors.forename: A
authors.initials: A
authors.lastname: Spencer
authors.forename: K
authors.initials: K
authors.lastname: Hill
authors.forename: A
authors.initials: A
authors.lastname: House
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010919:Placebos; D012106:Research; D012189:Retrospective Studies; D020521:Stroke / Q000523:psychology*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010919:Placebos; D005473:Fluoxetine